Online Program Home
My Program

Abstract Details

Activity Number: 380
Type: Contributed
Date/Time: Tuesday, August 2, 2016 : 10:30 AM to 11:15 AM
Sponsor: Biopharmaceutical Section
Abstract #321812
Title: Impact of Mis-Specified Prior on the Bayesian Dose-Finding Method in Phase I Cancer Trials
Author(s): Lixia Pei* and Kevin Liu and Hong Tian
Companies: Janssen R&D and Janssen R&D and Janssen R&D
Keywords: Dose finding ; Bayesian model-based design ; 3+3 ; mis-specified prior ; DLT ; MTD
Abstract:

In Phase I cancer trials, the target is to identify the maximum-tolerated dose (MTD), which is defined as the probability of dose-limiting toxicities (DLT) is closest to and lower than a targeted probability. The most widely used methods include the 3+3 design and Bayesian model-based designs. The 3+3 design has been widely used over the years because it's simple to be understood and implemented. The Bayesian model-based approach has gradually drawn more attention because it efficiently uses all observed data and also can include prior information. The objective of this work is to investigate the impact of mis-specified prior on Bayesian model-based design, which is motivated by the fact that in many clinical trials, the prior information is available only among animal studies. The species difference between animal and human could lead to a mis-specified prior. A comparison between 3+3 and Bayesian model-based dose finding designs will be provided in terms of operation characteristics. We will propose some guidelines in the choices of designs and priors based on the likelihood that the prior clinical knowledge would be consistent to the current dose finding trial.


Authors who are presenting talks have a * after their name.

Back to the full JSM 2016 program

 
 
Copyright © American Statistical Association